losartan has been researched along with aspirin in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 14 (46.67) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Babkov, DA; Babkova, VA; Borisov, AV; Borodkin, GS; Brigadirova, AA; Kolodina, AA; Litvinov, RA; Morkovnik, AS; Sochnev, VS; Sokolova, EV; Spasov, AA; Zhukowskaya, ON | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Abe, Y; Aki, Y; Kimura, S; Takenaka, I; Tamaki, T; Yoshida, H | 1 |
| Agostoni, P; Guazzi, M; Melzi, G | 1 |
| Cirigliano, MD; Nawarskas, JJ; Spinler, SA; Townsend, RR | 1 |
| Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ | 1 |
| Diener, HC | 1 |
| McCall, AL | 1 |
| Bobik, A | 1 |
| De Champlain, J; Laplante, MA; Wu, R | 1 |
| Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fossum, E; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Moan, A; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H | 1 |
| Levinson, JR; MacRae, CA; Nahed, BV; Naunheim, MR; Ogilvy, CS; Walcott, BP | 1 |
| Ding, Z; Goyal, T; Khaidakov, M; Lu, J; Mehta, JL; Mitra, S; Raina, S; Wang, X | 1 |
| Ayyadevera, S; Ding, Z; Goyal, T; Hearnsberger, E; Khaidakov, M; Mehta, JL; Mitra, S; Wang, X | 1 |
| Boytsov, S; Deev, A; Dupik, N; Kolos, I; Loukianov, M | 1 |
| Caglar, I; Karakaya, O; Ugurlucan, M; Ungan, I; Vural, A | 1 |
| Dunning, L; Ferrell, WR; Lockhart, JC; Mackenzie, A | 1 |
| Luteijn, JM; Morris, JK; Oppenheimer, P; Taylor, D; Wald, NJ | 1 |
| Kotegawa, T; Koya, Y; Machi, Y; Namiki, N; Shobu, Y; Uchida, S | 1 |
| Moreno Vanegas, Y; Rivera, CE; Vishnu, P; Wadei, HM | 1 |
| Dong, B; Dong, S; Li, L; Liu, Q; Shen, J; Yang, K; Zhao, Y; Zhou, X; Zhu, D | 1 |
3 review(s) available for losartan and aspirin
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Apical hypertrophic cardiomyopathy--case report and review of the literature.
Topics: Acute Coronary Syndrome; Aspirin; Cardiomyopathy, Hypertrophic; Echocardiography; Electrocardiography; Humans; Losartan; Magnetic Resonance Imaging; Male; Middle Aged; Mutation | 2013 |
5 trial(s) available for losartan and aspirin
| Article | Year |
|---|---|
Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiomyopathy, Dilated; Cross-Over Studies; Cyclooxygenase Inhibitors; Double-Blind Method; Enalapril; Exercise Test; Heart Failure; Hemodynamics; Humans; Losartan; Male; Middle Aged; Myocardial Ischemia; Oxygen Consumption; Pulmonary Diffusing Capacity; Pulmonary Ventilation; Respiratory Mechanics | 1997 |
Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Blood Pressure; Cross-Over Studies; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Interactions; Enalapril; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Patient Compliance; Thromboxane B2 | 1999 |
Reducing CVD risk in type 2 DM.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Behavior Therapy; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dietary Carbohydrates; Dietary Fats; Exercise; Humans; Insulin, Isophane; Losartan; Risk Factors; Smoking Cessation | 2003 |
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atenolol; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Treatment Outcome | 2005 |
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endarterectomy, Carotid; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Myocardial Infarction; Prospective Studies; Research Design; Russia; Stroke | 2015 |
22 other study(ies) available for losartan and aspirin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.
Topics: AMP-Activated Protein Kinases; Animals; Benzimidazoles; Biphenyl Compounds; Cattle; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Enzyme Activators; Glycosylation; Hypoglycemic Agents; Lipopolysaccharides; Macrophages; Mice; Nitric Oxide; Serum Albumin, Bovine; Solubility; Structure-Activity Relationship | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Effects of angiotensin II on isolated rabbit afferent arterioles.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Arterioles; Aspirin; Biphenyl Compounds; Imidazoles; In Vitro Techniques; Indomethacin; Losartan; Lysine; Male; Nitric Oxide; omega-N-Methylarginine; Prostaglandin Antagonists; Prostaglandins; Rabbits; Renal Circulation; Tetrazoles; Vascular Resistance | 1994 |
Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bleeding Time; Captopril; Disease Models, Animal; Endothelium, Vascular; Female; Hemodynamics; Losartan; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Refractory Period, Electrophysiological; Vasodilation; Ventricular Fibrillation | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
Aspirin, superoxide anions and development of hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Aspirin; Cells, Cultured; Hypertension; Losartan; Luminescent Measurements; Male; Muscle, Smooth, Vascular; Oxidative Stress; Rats; Rats, Sprague-Dawley; Superoxides; Time Factors; Vasoconstrictor Agents | 2004 |
Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Aspirin; Body Weight; Cells, Cultured; Hypertension; Hypertrophy, Left Ventricular; Losartan; Luminescent Measurements; Male; Muscle, Smooth, Vascular; Organ Size; Oxidative Stress; Rats; Rats, Sprague-Dawley; Superoxides; Time Factors; Vasoconstrictor Agents | 2004 |
Arterial tortuosity syndrome with multiple intracranial aneurysms: a case report.
Topics: Aged; Angiography; Antihypertensive Agents; Aorta; Aspirin; Circle of Willis; Connective Tissue Diseases; Coronary Vessels; Electrocardiography; Heart Block; Humans; Hypertension; Iliac Artery; Intracranial Aneurysm; Intracranial Arterial Diseases; Losartan; Male; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Syncope; Syndrome | 2011 |
Aspirin suppresses cardiac fibroblast proliferation and collagen formation through downregulation of angiotensin type 1 receptor transcription.
Topics: Angiotensin II; Animals; Aspirin; Cell Proliferation; Collagen; Down-Regulation; Fibroblasts; Losartan; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; NADPH Oxidases; NF-kappa B; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Transcription, Genetic | 2012 |
Aspirin downregulates angiotensin type 1 receptor transcription implications in capillary formation from endothelial cells.
Topics: Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Aspirin; Capillaries; Cells, Cultured; Down-Regulation; Enzyme Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Losartan; Mitogen-Activated Protein Kinases; NADPH Oxidases; Neovascularization, Physiologic; Receptor, Angiotensin, Type 1; RNA, Messenger; Salicylic Acid; Transcription, Genetic; Vascular Endothelial Growth Factor A | 2012 |
Angiotensin II Type 1 receptor blockade protects endothelium-derived hyperpolarising factor-mediated relaxation in a rat model of monoarthritis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Arthritis, Experimental; Aspirin; Charybdotoxin; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium-Dependent Relaxing Factors; Female; Losartan; Muscle Relaxation; Muscle, Smooth, Vascular; Myography; NG-Nitroarginine Methyl Ester; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1 | 2013 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort Studies; Cost-Benefit Analysis; Humans; Hydrochlorothiazide; Losartan; Markov Chains; Middle Aged; Myocardial Infarction; Polypharmacy; Primary Prevention; Quality-Adjusted Life Years; Simvastatin; Stroke; United Kingdom | 2016 |
Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
Topics: Administration, Oral; Adsorption; Aluminum Hydroxide; Amlodipine; Aspirin; Carbon; Drug Interactions; Glycine; Humans; Intestinal Absorption; Losartan; Magnesium; Metoprolol; Models, Biological; Nifedipine; Oxides; Renal Insufficiency, Chronic; Solubility; Triazolam | 2016 |
Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Hematocrit; Humans; Kidney Transplantation; Losartan; Male; Middle Aged; Pancreas Transplantation; Phlebotomy; Polycythemia; Treatment Outcome | 2018 |
Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats.
Topics: Animals; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Collagen; Hypertension; Interleukin-6; Losartan; Rats; Rats, Inbred SHR; Renin; Vascular Remodeling | 2023 |